Tropisetron — Safety, Research, Risks & Legal Status

Not medical advice. Tropisetron is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Navoban; ICS 205-930; SDZ-ICS-930; ICS-205-930
Category	Research Chemical
CAS Number	105826-92-4
Molecular Formula	C17H20N2O2·HCl
Primary Receptor Target	5-HT3 antagonist; secondary alpha7 nAChR partial agonist
International Approval	Approved 1992 (Navoban, Novartis) in EU, Australia, Japan, and others for CINV; not FDA-approved
Key Schizophrenia RCT Parameters	10 mg/day oral, 8 weeks, n=40, double-blind, placebo-controlled
CINV Safety Database	More than 80,000 patients; no marked extrapyramidal symptoms identified in safety review
US legal status	Not FDA-approved; no US marketing authorization. Available as a marketed pharmaceutical outside the US (Europe, Australia, New Zealand, Japan, South Korea, Philippines) under the brand name Navoban (Novartis). Listed in the FDA Global Substance Registration System (GSRS) and NCATS Inxight Drugs database as an identified substance. In the US, it has no approved indication and is not available by prescription; any domestic availability is outside approved pharmaceutical channels.

What is Tropisetron?

Tropisetron is a synthetic indole-derived compound that functions as a selective serotonin 5-HT3 receptor antagonist with secondary activity as a partial agonist at the alpha-7 nicotinic acetylcholine receptor (alpha7 nAChR). It was developed by Sandoz (now Novartis) and approved internationally in 1992 for the prevention of chemotherapy-induced nausea and vomiting (CINV). Its dual pharmacological profile has generated research interest in cognitive and neuropsychiatric conditions independent of its antiemetic use.

How it works

Tropisetron's primary approved mechanism is 5-HT3 receptor antagonism in the gastrointestinal tract and chemoreceptor trigger zone, blocking serotonin-mediated emetic signaling. Its secondary and more experimentally explored activity is partial agonism at the alpha7 nicotinic acetylcholine receptor. Alpha7 nAChRs are expressed throughout the hippocampus and prefrontal cortex; partial agonism at these receptors is theorized to sensitize them to low ambient acetylcholine concentrations, potentially facilitating pro-cognitive and sensory-gating effects. This alpha7 activity is considered mechanistically distinct from the antiemetic action and is the basis for ongoing neuropsychiatric investigation. Tropisetron has also been shown in animal studies to bind amyloid precursor protein (APP), though the relevance of this binding to human disease has not been established.

Background & history

Tropisetron was patented in 1982 and approved for medical use in 1992, originally by Sandoz under the brand Navoban. Following the 1996 Sandoz-Ciba-Geigy merger, the compound passed to Novartis. Its international approval established a large safety database - clinical antiemetic use has included more than 80,000 patients. Research into its alpha7 nAChR activity led to investigation as a cognitive enhancer beginning in the 2000s, with randomized controlled trials in schizophrenia and anxiety disorders reported by the early 2010s, and entry into human trials for mild cognitive impairment and Alzheimer's disease around 2014. It has never received FDA approval and is not available as a prescription medication in the United States.

What the research says

The human evidence base is limited but includes several controlled trials. A double-blind, placebo-controlled trial in patients with schizophrenia (10 mg/day over 8 weeks, n=40) reported cognitive benefits. A separate line of investigation found that tropisetron improves auditory P50 suppression deficits in schizophrenia - a putative biomarker of sensory gating and cognitive processing. A double-blind, placebo-controlled trial in generalized anxiety disorder has also been conducted. Animal studies show improved performance on memory tasks in young and aged rodents, normalization of cognition in murine Alzheimer's disease models, and enhancement of recognition memory in rats receiving antipsychotics (risperidone, quetiapine). APP binding has been reported in animal model work. Human trials for mild cognitive impairment and Alzheimer's disease were entered approximately 2014; long-term outcomes in these populations are not yet well-characterized in the published literature. The overall human cognitive evidence base remains limited and should not be extrapolated beyond the specific populations studied.

Reported effects

5-HT3 receptor antagonism producing antiemetic effects (approved international indication)
Alpha7 nAChR partial agonism, proposed to support cognitive and sensory-gating function in preclinical and limited clinical models
Reported cognitive improvement in a small randomized controlled trial in schizophrenia patients
Improvement in auditory P50 suppression deficits (a sensory-gating biomarker) in schizophrenia
Memory-task improvement in rodent models including aged animals and Alzheimer's disease models
Possible reduction of anxiety symptoms based on one controlled trial in generalized anxiety disorder - evidence limited

Dosing & administration (informational)

Published clinical literature reports antiemetic use at 5 mg intravenously or orally per cycle in adults; pediatric antiemetic dosing at approximately 0.1 mg/kg. The schizophrenia cognition RCT used 10 mg/day orally for 8 weeks. These figures appear in peer-reviewed publications for informational reference only and do not constitute a dosing protocol. Appropriate dose, route, duration, and monitoring for any individual use require evaluation by a licensed clinician familiar with the patient's full medical context. This site does not provide dosing recommendations.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Well-tolerated in antiemetic use across more than 80,000 patients; overall adverse event burden described as low in CINV literature
Most common adverse events: headache (up to 18%), constipation (up to 7.6%), fatigue (up to 3.5%)
No marked extrapyramidal symptoms reported in the large CINV safety review
Pediatric safety profile described as comparable to adults in chemotherapy settings
No prominent serious adverse events identified in the available literature at standard antiemetic doses
Cognitive/neuropsychiatric trial doses (e.g., 10 mg/day) are higher than some antiemetic regimens; long-term safety at these doses is not well-characterized
Standard drug interaction and contraindication assessment required; interactions with serotonergic drugs, QT-prolonging agents, and CYP enzyme substrates should be evaluated by a clinician

Drug & supplement interactions

S
e
r
o
t
o
n
e
r
g
i
c
d
r
u
g
s
(
S
S
R
I
s
,
S
N
R
I
s
,
M
A
O
I
s
,
o
t
h
e
r
5
-
H
T
3
a
n
t
a
g
o
n
i
s
t
s
)
m
a
y
i
n
t
e
r
a
c
t
g
i
v
e
n
s
h
a
r
e
d
s
e
r
o
t
o
n
e
r
g
i
c
t
a
r
g
e
t
s
.
Q
T
p
r
o
l
o
n
g
a
t
i
o
n
r
i
s
k
s
h
o
u
l
d
b
e
a
s
s
e
s
s
e
d
w
h
e
n
c
o
-
a
d
m
i
n
i
s
t
e
r
e
d
w
i
t
h
o
t
h
e
r
Q
T
-
p
r
o
l
o
n
g
i
n
g
a
g
e
n
t
s
.
A
s
a
c
o
m
p
o
u
n
d
m
e
t
a
b
o
l
i
z
e
d
v
i
a
c
y
t
o
c
h
r
o
m
e
P
4
5
0
p
a
t
h
w
a
y
s
,
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
C
Y
P
i
n
d
u
c
e
r
s
o
r
i
n
h
i
b
i
t
o
r
s
a
r
e
p
l
a
u
s
i
b
l
e
.
A
c
e
t
y
l
c
h
o
l
i
n
e
s
t
e
r
a
s
e
i
n
h
i
b
i
t
o
r
s
u
s
e
d
i
n
A
l
z
h
e
i
m
e
r
'
s
d
i
s
e
a
s
e
(
d
o
n
e
p
e
z
i
l
,
r
i
v
a
s
t
i
g
m
i
n
e
)
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
i
n
t
e
r
a
c
t
g
i
v
e
n
t
r
o
p
i
s
e
t
r
o
n
'
s
a
l
p
h
a
7
n
A
C
h
R
a
c
t
i
v
i
t
y
.
N
o
c
o
m
p
r
e
h
e
n
s
i
v
e
h
u
m
a
n
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
s
e
t
f
o
r
n
e
u
r
o
p
s
y
c
h
i
a
t
r
i
c
d
o
s
i
n
g
r
e
g
i
m
e
n
s
w
a
s
i
d
e
n
t
i
f
i
e
d
i
n
t
h
e
a
v
a
i
l
a
b
l
e
l
i
t
e
r
a
t
u
r
e
.
A
p
h
a
r
m
a
c
i
s
t
o
r
p
h
y
s
i
c
i
a
n
r
e
v
i
e
w
i
s
e
s
s
e
n
t
i
a
l
b
e
f
o
r
e
a
n
y
u
s
e
a
l
o
n
g
s
i
d
e
p
r
e
s
c
r
i
p
t
i
o
n
m
e
d
i
c
a
t
i
o
n
s
.

Who should avoid it

Concurrent use with other serotonergic agents without medical supervision
Use in individuals with known QT prolongation or on QT-prolonging medications without cardiac evaluation
Use in pregnancy or lactation - safety not established in these populations for non-antiemetic indications
Self-administration at cognitive-enhancement doses outside a clinical or supervised research context
Procurement from unregulated research chemical vendors where identity and purity cannot be verified

How it is commonly combined

No evidence-based stacking protocols exist for tropisetron in cognitive or nootropic contexts. The schizophrenia RCT administered tropisetron as an adjunct to existing antipsychotic regimens, suggesting that combination with antipsychotics was considered safe enough to study - but this was in a controlled clinical trial with monitoring. Combination with cholinesterase inhibitors has theoretical rationale given complementary mechanisms, but no human trial data supporting specific combinations was identified. Any combination use requires clinical oversight.

Legal & regulatory. Not FDA-approved; no US marketing authorization. Available as a marketed pharmaceutical outside the US (Europe, Australia, New Zealand, Japan, South Korea, Philippines) under the brand name Navoban (Novartis). Listed in the FDA Global Substance Registration System (GSRS) and NCATS Inxight Drugs database as an identified substance. In the US, it has no approved indication and is not available by prescription; any domestic availability is outside approved pharmaceutical channels.

Quality & harm reduction

T
r
o
p
i
s
e
t
r
o
n
i
s
a
w
e
l
l
-
c
h
a
r
a
c
t
e
r
i
z
e
d
p
h
a
r
m
a
c
e
u
t
i
c
a
l
c
o
m
p
o
u
n
d
w
i
t
h
a
c
o
n
f
i
r
m
e
d
C
A
S
n
u
m
b
e
r
(
1
0
5
8
2
6
-
9
2
-
4
)
,
m
o
l
e
c
u
l
a
r
f
o
r
m
u
l
a
(
C
1
7
H
2
0
N
2
O
2
·
H
C
l
)
,
a
n
d
e
x
t
e
n
s
i
v
e
m
a
n
u
f
a
c
t
u
r
i
n
g
h
i
s
t
o
r
y
a
s
a
n
a
p
p
r
o
v
e
d
d
r
u
g
o
u
t
s
i
d
e
t
h
e
U
S
.
I
t
i
s
a
v
a
i
l
a
b
l
e
a
s
a
r
e
s
e
a
r
c
h
-
g
r
a
d
e
r
e
f
e
r
e
n
c
e
s
t
a
n
d
a
r
d
f
r
o
m
c
h
e
m
i
c
a
l
s
u
p
p
l
i
e
r
s
(
e
.
g
.
,
C
a
y
m
a
n
C
h
e
m
i
c
a
l
)
.
P
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
v
e
r
i
f
i
c
a
t
i
o
n
b
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
a
r
e
s
t
a
n
d
a
r
d
e
x
p
e
c
t
a
t
i
o
n
s
f
o
r
a
n
y
r
e
s
e
a
r
c
h
-
g
r
a
d
e
s
u
p
p
l
y
.
N
o
p
e
e
r
-
r
e
v
i
e
w
e
d
d
a
t
a
o
n
t
h
e
p
u
r
i
t
y
o
r
a
u
t
h
e
n
t
i
c
i
t
y
o
f
g
r
a
y
-
m
a
r
k
e
t
o
r
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
s
u
p
p
l
y
c
h
a
i
n
s
w
a
s
i
d
e
n
t
i
f
i
e
d
;
s
o
u
r
c
i
n
g
f
r
o
m
u
n
r
e
g
u
l
a
t
e
d
v
e
n
d
o
r
s
c
a
r
r
i
e
s
u
n
k
n
o
w
n
a
d
u
l
t
e
r
a
t
i
o
n
r
i
s
k
.

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find Tropisetron →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is tropisetron approved in the United States?

No. Tropisetron has no FDA marketing approval and is not available as a prescription medication in the US. It is an approved pharmaceutical in Europe, Australia, New Zealand, Japan, South Korea, and the Philippines under the brand name Navoban (Novartis).

What dose should I use for cognitive enhancement?

This site does not provide dosing recommendations. The published schizophrenia cognition RCT used 10 mg/day orally for 8 weeks under clinical supervision. Appropriate dosing for any individual requires evaluation by a licensed clinician.

How does tropisetron differ from other 5-HT3 antagonists like ondansetron?

Most 5-HT3 antagonists (ondansetron, granisetron) act selectively at that receptor. Tropisetron is distinctive in its secondary partial agonist activity at the alpha7 nicotinic acetylcholine receptor, which is the proposed basis for its cognitive and neuropsychiatric research interest. This dual pharmacology sets it apart mechanistically within the class.

What is the strength of the human evidence for cognitive effects?

Limited but controlled. The best available human evidence is a small double-blind, placebo-controlled trial in schizophrenia patients (n=40, 8 weeks) reporting cognitive benefits, plus P50 sensory-gating biomarker improvements in schizophrenia. A generalized anxiety disorder RCT has also been conducted. Human data in Alzheimer's disease or healthy populations is not well-characterized in the published literature. Animal model data is more extensive. These results cannot be generalized to healthy individuals or broader populations without further research.

Is tropisetron safe to use?

The safety profile in its approved antiemetic indication is well-characterized and generally favorable across a large patient population, with mild common adverse events (headache, constipation, fatigue). Long-term safety at the higher doses used in cognitive research trials is less well-studied. Any use outside a clinical setting and without medical supervision carries risks that cannot be quantified from publicly available data.

Does tropisetron have anything to do with Alzheimer's disease research?

It has been investigated in preclinical Alzheimer's models. Animal studies report cognitive normalization and binding to amyloid precursor protein (APP). Human trials for mild cognitive impairment and Alzheimer's disease were reportedly initiated around 2014. However, no large-scale human trial results establishing efficacy in these populations were identified in the available literature; this remains an investigational area.

References & further reading

PubMed PMID 11212100 - mechanism: alpha7 nAChR partial agonism by tropisetron
PubMed PMID 20573264 - randomized controlled trial in schizophrenia cognition
PubMed PMC4001856 / PMID 24095189 - APP binding and Alzheimer's cognition in murine model
ClinicalTrials.gov NCT01636947 - Phase 4 nausea/vomiting trial (completed 2012)
PubMed: search 'tropisetron alpha7 nicotinic acetylcholine receptor cognition' for mechanistic literature; search 'tropisetron schizophrenia P50 auditory gating' for biomarker studies